The global food allergy treatment market was valued at approximately USD 6,872.9 million in 2024 and is expected to grow to USD 11,332.1 million by 2030, with a compound annual growth rate (CAGR) of 8.3% from 2025 to 2030. This growth is driven by the increasing prevalence of food allergies globally, alongside heightened research and development efforts for new treatments. Additionally, the adoption of innovative biological agents for food allergy treatment and a rise in clinic visits from patients seeking therapy are likely to further propel market growth during the forecast period.Food allergies, particularly to dairy and peanuts, are increasingly common among children in Western countries. Peanut allergies, which often persist into adulthood, typically begin in early childhood and are associated with more severe reactions compared to other food allergies. Unlike many allergies that may resolve as children grow older, peanut allergies tend to remain throughout life for most individuals.
Historically, managing food allergies has involved strict avoidance of allergens and emergency action plans, including the use of adrenaline auto-injectors. However, the 2018 guidelines from the European Academy of Allergy and Clinical Immunology (EAACI) have recommended Oral Immunotherapy (OIT) as a viable treatment for children as young as 4 to 5 years old. This shift reflects the increasing prevalence of food allergies and emphasizes the need for innovative treatments that can improve management strategies and potentially lessen the severity of allergic reactions.
Key Market Trends & Insights
• North America led the food allergy treatment market in 2024, capturing the largest revenue share of 39.14%. This dominance is attributed to a growing awareness of the significant potential of allergy medications, prompting U.S. companies to invest heavily in their development.
• In terms of allergen type, the peanut segment held the largest revenue share at 20.55% in 2024 and is anticipated to experience the fastest growth rate. This is driven by the increasing prevalence of peanut allergies globally and heightened research and development for new treatments.
• Among drug types, the epinephrine segment accounted for 41.0% of the market share in 2024, as it is the preferred medication for allergic reactions. Its growth is fueled by the rising incidence of food allergies, affecting over 32 million Americans and around 10% of the population in certain Asia-Pacific countries.
• By route of administration, the parenteral segment led with a revenue share of 54.90% in 2024 and is expected to grow at a CAGR of 10.12%. Epinephrine, primarily administered via intramuscular injection into the thigh, is the main treatment for anaphylaxis.
• In terms of end use, hospital pharmacies dominated the market with a revenue share of 55.48% in 2024. The increasing number of hospital pharmacies is a key growth driver, enhancing access to treatments like antihistamines, epinephrine auto-injectors, and newer immunotherapy options.
Order a free sample PDF of the Food Allergy Treatment Market Intelligence Study, published by Grand View Research.